NCT02654561

Efficacy and Safety of Unfractionated Heparin on Severe Sepsis With Suspected Disseminated Intravascular Coagulation

Name: Clinical Trial NCT02654561
Creator: China Medical University, China
Keywords: Sepsis,Disseminated Intravascular Coagulation, Heparin Sodium, Phase 3, drug, clinical trial, China

Phase 3 Study of the Efficacy and Safety of Unfractionated Heparin in Patients With Severe Sepsis/Septic Shock With Suspected DIC

China Medical University, China·Phase 3·ClinicalTrials.gov·drug

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Sepsis,Disseminated Intravascular Coagulation
Drug/Device/Intervention: Heparin Sodium
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: China Medical University, China
Location: Haerbin,Changsha,Nanjing,Dalian,Dalian,Shenyang,Shenyang,Qingdao,Chengdu,Kunming,Kunming,Beijing,Beijing,Beijing,Jilin,Qinhuangdao,Shenyang, China

Timeline & enrollment

Phase: Phase 3
Start date: Apr 20, 2017
End date: Jun 01, 2021
Enrollment: 700 participants

Primary outcome

ICU mortality

Summary

The primary objective of this study is to estimate the efficacy of unfractionated heparin(UFH) on ICU mortality in severe sepsis with suspected DIC.The Second objective is to estimate the effect of UFH on 28-day mortality,and the change of the Japanese Association for Acute Medicine(JAAM) score and SOFA score. The third one is to evaluate the safety of UFH in severe sepsis patients with suspected DIC.

ICD-10 classifications

Disseminated intravascular coagulation of fetus and newbornDisseminated intravascular coagulation [defibrination syndrome]Sepsis, unspecifiedOther specified sepsisOther sepsis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT02654561
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT02654561 through Pure Global AI's free database. This Phase 3 trial is sponsored by China Medical University, China and is currently status unknown. The study focuses on Sepsis,Disseminated Intravascular Coagulation. Target enrollment is 700 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.